242 related articles for article (PubMed ID: 30334354)
1. Application of immunophenotypic analysis in distinguishing chronic myelomonocytic leukemia from reactive monocytosis.
Feng R; Bhatt VR; Fu K; Pirruccello S; Yuan J
Cytometry B Clin Cytom; 2018 Nov; 94(6):901-909. PubMed ID: 30334354
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis.
Xu Y; McKenna RW; Karandikar NJ; Pildain AJ; Kroft SH
Am J Clin Pathol; 2005 Nov; 124(5):799-806. PubMed ID: 16203279
[TBL] [Abstract][Full Text] [Related]
3. [Significance and application value of multiparameter flow cytometry for differentiation of immunophenotype in chronic myelomonocytic leukemia, myelodysplastic syndrome and acute monocytic leukemia].
Wang YX; Zhang JH; Hu YP; Cao FF; Zhang N; Chen F; Liu X; Zhang MY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):857-62. PubMed ID: 22931642
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response.
Shen Q; Ouyang J; Tang G; Jabbour EJ; Garcia-Manero G; Routbort M; Konoplev S; Bueso-Ramos C; Medeiros LJ; Jorgensen JL; Wang SA
Eur J Haematol; 2015 Aug; 95(2):168-76. PubMed ID: 25354960
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotypes of Chronic Myelomonocytic Leukemia (CMML) Subtypes by Flow Cytometry: A Comparison of CMML-1 vs CMML-2, Myeloproliferative vs Dysplastic, De Novo vs Therapy-Related, and CMML-Specific Cytogenetic Risk Subtypes.
Harrington AM; Schelling LA; Ordobazari A; Olteanu H; Hosking PR; Kroft SH
Am J Clin Pathol; 2016 Aug; 146(2):170-81. PubMed ID: 27413139
[TBL] [Abstract][Full Text] [Related]
6. Monocyte subsets to differentiate chronic myelomonocytic leukemia from reactive monocytosis.
Hwang SM; Ahn H; Jeon S; Park J; Chang Y; Kim H
J Clin Lab Anal; 2021 Jan; 35(1):e23576. PubMed ID: 32931067
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?
Subirá D; Font P; Villalón L; Serrano C; Askari E; Góngora E; Castañón S; Gonzalo R; Mata R; Román A; Llamas P
Transl Res; 2008 May; 151(5):240-5. PubMed ID: 18433705
[TBL] [Abstract][Full Text] [Related]
8. The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis.
Cargo C; Cullen M; Taylor J; Short M; Glover P; Van Hoppe S; Smith A; Evans P; Crouch S
Blood; 2019 Mar; 133(12):1325-1334. PubMed ID: 30606702
[TBL] [Abstract][Full Text] [Related]
9. Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells.
Kern W; Bacher U; Haferlach C; Schnittger S; Haferlach T
Leuk Lymphoma; 2011 Jan; 52(1):92-100. PubMed ID: 21219126
[TBL] [Abstract][Full Text] [Related]
10. High sensitivity of the Hematoflow™ solution for chronic myelomonocytic leukemia screening.
Vazquez R; Roussel M; Badaoui B; Freynet N; Tarfi S; Solary E; Selimoglu-Buet D; Wagner-Ballon O;
Cytometry B Clin Cytom; 2018 Sep; 94(5):658-661. PubMed ID: 29108126
[TBL] [Abstract][Full Text] [Related]
11. Real world implementation of flow cytometric monocyte subset partitioning for distinguishing chronic myelomonocytic leukaemia from other causes of monocytosis.
Barge L; Gooch M; Hendle M; Simleit E
Pathology; 2023 Oct; 55(6):827-834. PubMed ID: 37541805
[TBL] [Abstract][Full Text] [Related]
12. Chronic myelomonocytic leukemia monocytes uniformly display a population of monocytes with CD11c underexpression.
Sojitra P; Gandhi P; Fitting P; Kini AR; Alkan S; Velankar MM; Venkataraman G
Am J Clin Pathol; 2013 Nov; 140(5):686-92. PubMed ID: 24124148
[TBL] [Abstract][Full Text] [Related]
13. Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features.
Calvo X; Garcia-Gisbert N; Parraga I; Gibert J; Florensa L; Andrade-Campos M; Merchan B; Garcia-Avila S; Montesdeoca S; Fernández-Rodríguez C; Salido M; Puiggros A; Espinet B; Colomo L; Roman-Bravo D; Bellosillo B; Ferrer A; Arenillas L
Blood Adv; 2020 Oct; 4(20):5285-5296. PubMed ID: 33108455
[TBL] [Abstract][Full Text] [Related]
14. Evaluation by Flow Cytometry of Mature Monocyte Subpopulations for the Diagnosis and Follow-Up of Chronic Myelomonocytic Leukemia.
Picot T; Aanei CM; Flandrin Gresta P; Noyel P; Tondeur S; Tavernier Tardy E; Guyotat D; Campos Catafal L
Front Oncol; 2018; 8():109. PubMed ID: 29707521
[TBL] [Abstract][Full Text] [Related]
15. Clinical Utility of Classical and Nonclassical Monocyte Percentage in the Diagnosis of Chronic Myelomonocytic Leukemia.
Hudson CA; Burack WR; Leary PC; Bennett JM
Am J Clin Pathol; 2018 Aug; 150(4):293-302. PubMed ID: 29982327
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometry immunophenotypic characteristics of monocytic population in acute monocytic leukemia (AML-M5), acute myelomonocytic leukemia (AML-M4), and chronic myelomonocytic leukemia (CMML).
Gorczyca W
Methods Cell Biol; 2004; 75():665-77. PubMed ID: 15603447
[No Abstract] [Full Text] [Related]
17. Incorporating flow cytometry and next-generation sequencing in the diagnosis of CMML. Are we ready for prime?
Solary E; Wagner-Ballon O; Selimoglu-Buet D
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101134. PubMed ID: 32460985
[TBL] [Abstract][Full Text] [Related]
18. ELN iMDS flow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry.
Wagner-Ballon O; Bettelheim P; Lauf J; Bellos F; Della Porta M; Travaglino E; Subira D; Lopez IN; Tarfi S; Westers TM; Johansson U; Psarra K; Karathanos S; Matarraz S; Colado E; Gupta M; Ireland R; Kern W; Van De Loosdrecht AA;
Cytometry B Clin Cytom; 2023 Jan; 104(1):66-76. PubMed ID: 34967500
[TBL] [Abstract][Full Text] [Related]
19. Flow Cytometric Analysis of Monocytes and Granulocytes May Be Useful in the Distinction of Myeloid Neoplasms from Reactive Conditions: A Single Institution Experience and Literature Review.
Brown LE; Zhang D; Cui W
Ann Clin Lab Sci; 2020 May; 50(3):327-332. PubMed ID: 32581021
[TBL] [Abstract][Full Text] [Related]
20. Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.
Hu Z; Ramos CEB; Medeiros LJ; Zhao C; Yin CC; Li S; Hu S; Wang W; Thakral B; Xu J; Verstovsek S; Lin P
Hum Pathol; 2019 Mar; 85():290-298. PubMed ID: 30447300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
